morn tw compani announc ould miss consensu due -- varian var-not cover
pki- cover meehan life scienc diagnost analyst
 includ commentari varian confer call believ varian commentari applic
capit sensit like also like impact compani broadli ith busi china compani
embed disrupt guidanc hile other taken ait see approach like ho
includ guidanc viru continu spread like impact could still ors
provid summari commentari across coverag univers expect hear updat impact
throughout virtual confer eek ould surpris see preannounc across coverag univers
varian one mani med-tech compani attend barclay healthcar confer hich kick today ith
pre-confer event today host robot virtual cocktail hour pleas keep check confer
link click updat schedul
pleas chat bloomberg email session
thank understand patienc
ticker coverag barclay research inform compani provid
inform purpos invest recommend barclay research
varian preannounc lower sale driven
varian announc sale result ould consensu million vs bloomberg million ow ing
impact manag note china radiat oncolog perform inpati unlik geographi
deliv outpati see delay hardw softw instal accept ell deliveri
manag reduc full year grow th rate prior revenu grow th estim
announc today ill neg impact compani oper result
across asia pacif geographi healthcar resourc priorit treatment manag outbreak
consequ experienc delay hardw softw instal accept ell deliveri intervent
 hile order cancel expect revenu neg impact estim revenu rang
 hile uncertainti remain around durat sever geograph scope outbreak estim preliminari revenu
grow th outlook could shift outlook chang materi close monitor situat
prioriti protect employe support custom make sure patient access cancer fight technolog
long-term fundament remain strong continu plan invest drive long term grow th profit
 ill provid updat call
disrupt happen radiat therapi inpati procedur china expect long term
doubl digit grow th trend continu start see hospit transit normal oper ere provinc ere
hit quit hard ith coronaviru oncolog treat inpati china hospit alloc bed caus
delay ith instal continu forw ard progress provinc net promot score
time continu high abl provid servic manag note feel good
market percept continu good also feel good come back normalci china next
area seen small impact asia pacif japan impact southeast asia itali thing orsen
europ could increment risk varian atch hat bake china japan korea itali
what assum return normalci what guidanc havent seen order cancel china confid
come back think question time think delay varian manag think delay bridg
year think revenu ill come hospit relat public tender indic busi ill
come back varian see resumpt activ see chang long term profil market
manag believ demand technolog china strong tender licens cancel
interim paus tender cancel healthcar resourc china focus manag
think busi ill come back
order profil tender licens cancel seen paus public tender delay
push right thing inpati resourc china bit differ bed use
action margin take cost action also spend make sure peopl safe earli get arm
around cost side continu make plan invest long-term revenu compound-annual-growth-rate investor day remain
earli give oper margin guid dont guid gross margin import understand primari oncolog proton
hardw deliv vault servic softw deliv delay softw servic hardw order etho
demand remain high global continu gain market share
china sale ere million repres total compani sale china sale across busi
manag yet comment potenti impact busi
avano note potenti neg impact suppli chain oper compani sourc
finish good neom line enter feed devic neonat pediatr patient along ith compon
use manufactur devic facil china avano express confid abil manag suppli issu
minim disrupt
compon axon sacral neuromodul system made unit state batteri
compon recharg pack sourc china though compani believ suffici inventori
anticip impact suppli
china sale repres sale
manag comment china sale renal account major exposur focus ensur
integr suppli chain support patient end issu ith suppli manufactur facil
baxter seen increas acut therapi patient ith acut kidney issu low er volum basic iv sale low er
sale anesthesia gase due peopl avoid hospit er elect procedur
manag also note larg busi europ continu monitor busi hich fine
viru spread itali
china billion busi total compani sale
 ithin lifesci busi manag note receiv sever urgent order bd molecular system
coronaviru test ever net/net manag estim coronaviru expect million headw ind
china repres approxim million sale approxim revenu
includ approxim million neg impact guidanc though manag also
believ could come back
china repres sale
compani product compon sourc countri impact coronaviru ever
manufactur side manag comment compani under-index china rel
edw ard signific product directli china
 estim china sale approxim million slightli less sale
china particular focu among emerg market grow th hillrom
similar varian believ may push capit sale hillrom china quarter
asia pacif revenu repres js total sale
march issu busi continu statement detail impact segment action
compani take prevent spread viru compani busi continu plan place hich includ maintain
critic inventori major distribut center ork ith extern supplier support prepared plan also
launch multi-prong respons primarili around develop vaccin screen antivir therapi
compani partner ith hhss biomed advanc research develop author barda expedit
investig vaccin program though potenti candid like month avail
pharmaceut compani forese pharmaceut suppli interrupt relat
investor confer manag note could see low er demand close limit hour infus center
medic devic vast major js global medic devic manufactur run near normal capac
includ plant china investor confer manag call signific declin elect surgeri
anticip track overal market
consum compani anticip signific suppli risk result demand side
manag expect modest impact particularli around skin care though perhap off-set self-car
china repres approxim compani global sale
includ impact financi outlook said ill provid updat
greater insight impact
addit sale exposur purchas compon raw materi servic numer supplier china
rel low presenc china hich repres roughli global revenu
suppli chain perspect compani three manufactur facil china manag comment
run though full capac
investor confer earli march manag note expect neg revenu impact like though
specifi amount essenti elect surgeri china stop manag note ill like provid
adjust number ith result provid investor sens impact
teleflex china busi million repres sale
estim neg impact approxim million
china repres slightli less compani global revenu
zimmer biomet manag note seen reduct elect procedur februari manag
expect headw ind minimum continu march manag note also see headw ind broader apac
though yet scale china lastli zb monitor trend emea primarili europ middl eastern
countri ell us
suppli chain perspect three compani manufactur facil locat china local-
for-loc local-for-glob manufactur three facil product better
manag note us dollar strengthen asian european currenc zb anticip greater fx
headw ind contempl initi guidanc
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
co usd equal eight/neutr a/cd/ce/d/e/j/k/l/m/n
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli price-to-earnings multipl calendar ep
risk may imped achiev barclay research valuat price upsid new product drive
acceler sale ep grow th accret acquisit continu favor hospit capital-expenditure environ
nside less favor trend hospit capital-expenditure slow er uptak new product strengthen us dollar higher tax rate
risk includ signific reimburs chang fda product approv time competit pressur fda
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli target pe calendar ep estim slight discount med-tech
compani trade grow th profil improv expect pe expand closer peer
risk may imped achiev barclay research valuat price nside risk includ fx rate
strengthen us dollar hich could pressur earn stock perform new product key futur success
compani thu extent compani unabl receiv fda approv could advers impact futur
outlook product includ compani surgic robot platform minim futur iter continu blood glucos
monitor devic transcathet valv system upsid greater success ith new product margin expans risk
includ signific reimburs chang competit pressur product failur fda govern action
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
